Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

Korean preclinical CRO CorestemChemon is expanding its offerings through a partnership with ATG Lifetech, with the goal of ...

The FDA is amplifying an effort underway at medical device distributor Medline that aims to correct certain neurosurgery kits ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

The portable MRI manufacturer Hyperfine has begun rolling out the next generation of its artificial intelligence-equipped scanner-on-wheels, following an FDA green light last month.  | The Fierce ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

Medtronic has secured a new approval in Europe, greatly expanding the reach of its MiniMed 780G pump system—including for ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

The three-year-old spinout from Zimmer Biomet has reached the end of its road. | The three-year-old spinout from Zimmer ...